Concurrent Investment Advisors LLC Acquires 439 Shares of Edwards Lifesciences Co. (NYSE:EW)

Concurrent Investment Advisors LLC increased its holdings in Edwards Lifesciences Co. (NYSE:EW) by 2.3% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 19,626 shares of the medical research company’s stock after purchasing an additional 439 shares during the period. Concurrent Investment Advisors LLC’s holdings in Edwards Lifesciences were worth $1,453,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of EW. Migdal Insurance & Financial Holdings Ltd. purchased a new position in Edwards Lifesciences during the fourth quarter worth $30,000. FSA Wealth Management LLC purchased a new position in Edwards Lifesciences during the third quarter worth $30,000. Prospera Private Wealth LLC purchased a new position in Edwards Lifesciences during the third quarter worth $32,000. Avior Wealth Management LLC boosted its stake in Edwards Lifesciences by 138.7% during the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock worth $35,000 after buying an additional 308 shares during the period. Finally, Roble Belko & Company Inc purchased a new position in Edwards Lifesciences during the fourth quarter worth $46,000. Institutional investors own 79.46% of the company’s stock.

Analyst Ratings Changes

EW has been the subject of several recent analyst reports. Evercore ISI dropped their price objective on shares of Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating for the company in a research note on Wednesday, February 12th. Piper Sandler boosted their target price on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a research note on Wednesday, February 12th. The Goldman Sachs Group boosted their target price on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, December 5th. Daiwa America lowered shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 30th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $85.00 target price on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Hold” and a consensus target price of $79.95.

Insider Activity

In related news, VP Daniel J. Lippis sold 500 shares of the company’s stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $68.76, for a total value of $34,380.00. Following the sale, the vice president now owns 23,189 shares in the company, valued at $1,594,475.64. This represents a 2.11 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 6,500 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $75.75, for a total value of $492,375.00. Following the completion of the sale, the vice president now owns 46,936 shares in the company, valued at approximately $3,555,402. This represents a 12.16 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 26,489 shares of company stock worth $2,002,829 over the last 90 days. 1.29% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Stock Performance

EW opened at $73.25 on Friday. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The company has a market cap of $43.20 billion, a P/E ratio of 10.51, a price-to-earnings-growth ratio of 4.82 and a beta of 1.10. The firm’s 50-day moving average price is $72.85 and its 200-day moving average price is $70.00.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. As a group, equities analysts anticipate that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.